Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Docetaxel in Advanced Lung Adenocarcinoma
NCT02691871Phase 1Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in lung adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Dose Limiting Toxicity at 3 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02691871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691871.